Friday, October 21, 2022
Lantern Pharma Inc., a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,471,431, for Lantern’s drug candidate LP-300, which is in a Phase 2 clinical trial, Harmonic™, for never-smokers with relapsed non-small cell lung cancer (NSCLC).
The patent is directed to increasing the survival time of cancer patients receiving LP-300 for cancers that are marked by overexpression of the regulatory proteins thioredoxin (TRX) or glutaredoxin (GRX) and/or exhibition of TRX- or GRX-mediated resistance to one or more chemotherapeutic interventions. TRX and GRX are commonly overexpressed in adenocarcinomas, a cancer subtype of NSCLC, and can lead to increased tumor resistance to chemotherapy. LP-300 can inhibit activity of TRX and GRX, restoring the redox balance of cancer cells and improving their sensitivity to chemotherapy.
“Developing a strong and evolving patent estate around our drug candidates and technologies is an essential part of our business strategy. LP-300 has the potential to improve the lives of many cancer patient groups, including never-smokers with NSCLC,” said Panna Sharma, Lantern President and CEO. “The issuance of this patent demonstrates our ability to create unique cancer insights that we can then translate into clinical practice. This has the potential to add significant value for patients and investors alike,” continued Sharma.
U.S. Patent No. 11,471,431 is the latest U.S. patent added to LP-300’s patent portfolio. Lantern’s current patent estate for LP-300 includes 43 patents, covering 8 patent families. The strengthened patent estate relating to LP-300 will stimulate the opportunity for future partnering discussions with biopharma companies.
